Literature DB >> 20874702

The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders I: Parkinson's disease.

Helineide Cristina Campos1, Miguel Divino da Rocha, Flávia Pereira Dias Viegas, Patrícia Carolina Nicastro, Poliana Calve Fossaluzza, Carlos Alberto Manssour Fraga, Eliezer J Barreiro, Claudio Viegas.   

Abstract

Neurodegenerative disorders such as Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS) are currently incurable pathologies with huge social and economic impacts closely related to the increasing of life expectancy in modern times. Although the clinical and neuropathological aspects of these debilitating disorders are distinct, they share a pattern of neurodegeneration in anatomically or functionally related regions. For each disease, presently available treatments only address symptoms and do not alter the course or progression of the underlying diseases. In this context, the search for new effective chemical entities, capable of acting on diverse biochemical targets, with new mechanisms of action and low toxicity are genuine challenges to research groups and the pharmaceutical industry. This medical need has led to the reemerging of modern natural products chemistry that has yielded sophisticated and complex new lead molecules for drug discovery and development. In this review we discuss some of the main contributions of the natural products chemistry that covers multiple and varied plant species. Advances in the discovery of active constituents of plants, herbs, and extracts prescribed by traditional medicine practices for the treatment of senile neurodegenerative disorders, especially for PD, in the period after the 2000s is reviewed. The most important contributions from the 1990s are also discussed. The review also focuses on the pharmacological mechanisms of action that might underlie the purported beneficial improvements in memory and cognition, neurovascular function, and in neuroprotection. It is concluded that natural product chemistry brings tremendous diversity and historical precedent to a huge area of unmet medical need.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20874702     DOI: 10.2174/187152711794480483

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  10 in total

1.  The Rational Discovery of a Tau Aggregation Inhibitor.

Authors:  David W Baggett; Abhinav Nath
Journal:  Biochemistry       Date:  2018-10-05       Impact factor: 3.162

Review 2.  Herbal medicines for Parkinson's disease: a systematic review of randomized controlled trials.

Authors:  Tae-Hun Kim; Ki-Ho Cho; Woo-Sang Jung; Myeong Soo Lee
Journal:  PLoS One       Date:  2012-05-15       Impact factor: 3.240

3.  Anti-oxidant polydatin (piceid) protects against substantia nigral motor degeneration in multiple rodent models of Parkinson's disease.

Authors:  Yupin Chen; Dong-qi Zhang; Zhong Liao; Bin Wang; Suzhen Gong; Chuang Wang; Ming-zi Zhang; Guo-hua Wang; Huaibin Cai; Francesca-Fang Liao; Jiang-ping Xu
Journal:  Mol Neurodegener       Date:  2015-03-02       Impact factor: 14.195

4.  Cucurbitacin E has neuroprotective properties and autophagic modulating activities on dopaminergic neurons.

Authors:  Anne-Marie Arel-Dubeau; Fanny Longpré; Julie Bournival; Cindy Tremblay; Julie Demers-Lamarche; Pavlina Haskova; Everaldo Attard; Marc Germain; Maria-Grazia Martinoli
Journal:  Oxid Med Cell Longev       Date:  2014-12-09       Impact factor: 6.543

5.  Verbascoside promotes the regeneration of tyrosine hydroxylase-immunoreactive neurons in the substantia nigra.

Authors:  Jian-Qing Liang; Li Wang; Jian-Cheng He; Xian-Dong Hua
Journal:  Neural Regen Res       Date:  2016-01       Impact factor: 5.135

Review 6.  Forestalling the Epidemics of Parkinson's Disease Through Plant-Based Remedies.

Authors:  Ines Banjari; Tihana Marček; Svetlana Tomić; Viduranga Y Waisundara
Journal:  Front Nutr       Date:  2018-10-30

7.  Isolation and Characterization of NP-POL Nonapeptide for Possible Therapeutic Use in Parkinson's Disease.

Authors:  Marta Lemieszewska; Antoni Polanowski; Tadeusz Wilusz; Agata Sokołowska; Aleksandra Zambrowicz; Katarzyna Mikołajewicz; Józefa Macała; Joanna Rymaszewska; Agnieszka Zabłocka
Journal:  Oxid Med Cell Longev       Date:  2018-07-18       Impact factor: 6.543

8.  Optimization of 1,4-bis(arylsulfonamido)naphthalene-N,N'-diacetic acids as inhibitors of Keap1-Nrf2 protein-protein interaction to suppress neuroinflammation.

Authors:  Dhulfiqar Ali Abed; Sumi Lee; Xia Wen; Ahmed R Ali; Vaibhav Mangipudy; Lauren M Aleksunes; Longqin Hu
Journal:  Bioorg Med Chem       Date:  2021-07-01       Impact factor: 3.461

9.  Salvianolic acid B attenuates toxin-induced neuronal damage via Nrf2-dependent glial cells-mediated protective activity in Parkinson's disease models.

Authors:  Jie Zhou; Xiao-Dong Qu; Zhi-Yun Li; Qi Liu; Yi-Hui Ma; Jiao-Jiang He
Journal:  PLoS One       Date:  2014-07-03       Impact factor: 3.240

10.  α-Mangostin Inhibits α-Synuclein-Induced Microglial Neuroinflammation and Neurotoxicity.

Authors:  Zhaoyang Hu; Wei Wang; Jing Ling; Chunming Jiang
Journal:  Cell Mol Neurobiol       Date:  2016-03-22       Impact factor: 5.046

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.